Patents by Inventor José Alain Sahel

José Alain Sahel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11428698
    Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 30, 2022
    Assignees: Institut National de la Santé et de la Recherche Médicale, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQU—CNRS
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
  • Publication number: 20220249700
    Abstract: Disclosed herein are embodiments of a polymer-based implant and methods of making and using the same. The polymer-based implant comprises a polymer component and a therapeutic agent. In some embodiments, the polymer-based implant can be used to treat and/or prevent retinal diseases and/or retinopathies. The polymer-based implant exhibits physical properties that provide the ability to safely place the polymer-based implant in an ocular region without undesired diffusion and also to allow for controlled and timely release of the therapeutic agent to a desired region of the ocular region, such as the retina. In particular disclosed embodiments, the polymer-based implant can be used for safe and effective gene therapy.
    Type: Application
    Filed: May 12, 2020
    Publication date: August 11, 2022
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Morgan Fedorchak, Leah Byrne, José-Alain Sahel
  • Patent number: 11390866
    Abstract: The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 19, 2022
    Assignees: SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Deniz Dalkara, Serge Picaud, Melissa Desrosiers, Jose-Alain Sahel, Jens Duebel, Alexis Bemelmans, Botond Roska
  • Patent number: 11313852
    Abstract: The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 26, 2022
    Assignees: INSERM Institut National de la Sante er de la Recherche Medicale, CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Ludivine Perrocheau, Alain Van Dorsselaer, Jose Alain Sahel, Thierry Leveillard
  • Publication number: 20220040333
    Abstract: The present invention concerns a neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency.
    Type: Application
    Filed: July 13, 2021
    Publication date: February 10, 2022
    Inventors: Marisol Corral-Debrinski, Christophe Lechauve, José-Alain Sahel, Thomas Debeir
  • Patent number: 11191807
    Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 7, 2021
    Assignees: SARBONNE INIVERSIÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE TUNIS
    Inventors: Xavier Guillonneau, Fadoua Montassar, Naziha Marrakchi, Erij Messadi, Florian Sennlaub, José-Alain Sahel
  • Patent number: 11142548
    Abstract: Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: October 12, 2021
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Florian Sennlaub, Michael Housset, Xavier Guillonneau, José-Alain Sahel, Philippe Karoyan
  • Publication number: 20210308169
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising i) a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence and ii) a nucleotide sequence coding for a neurotrophic factor for use in the treatment of a retinal degenerative disease.
    Type: Application
    Filed: January 9, 2018
    Publication date: October 7, 2021
    Inventors: Jose-Alain SAHEL, Serge PICAUD, Thierry LEVEILLARD, Deniz DALKARA, Jens DUEBEL, Botond ROSKA
  • Publication number: 20210292785
    Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3?UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3?UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.
    Type: Application
    Filed: May 26, 2021
    Publication date: September 23, 2021
    Inventors: Marisol CORRAL-DEBRINSKI, Jose-Alain Sahel, Valerie Kaltimbacher, Crystel Bonnet
  • Publication number: 20210268125
    Abstract: Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.
    Type: Application
    Filed: October 22, 2018
    Publication date: September 2, 2021
    Inventors: DENIZ DALKARA, HANEN KHABOU, JOSÉ-ALAIN SAHEL, THIERRY LEVEILLARD, JENS DUEBEL
  • Patent number: 11080523
    Abstract: Disclosed is a method for pattern recognition in a plurality of received time signals of different types, the method includes: b) for each received signal, creating an asynchronous time signal including events; c) for each created asynchronous signal, creating an activity profile of the asynchronous signal which decreases as a function of the time elapsed since the last event of the asynchronous signal; d) for a given time t0: d1) determining a context defined as the set of activity profiles of the created asynchronous signals, d2) determining a standard context among predetermined standard contexts, having a minimum distance to the context determined in step d1, d3) determining the pattern as a function of the determined standard context.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 3, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Kevin Gehere, Germain Haessig, Ryad Benosman, Sio Hoi Ieng, José-Alain Sahel, Guillaume Chenegros, Nicolas Libert
  • Patent number: 11072661
    Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: July 27, 2021
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Florian Sennlaub, Bertrand Callippe, Xavier Guillonneau, José-Alain Sahel
  • Publication number: 20210085172
    Abstract: A method of analyzing a visual field of an individual comprises the following steps:—measuring (S4) a first visual field (VF1) of said individual for a first set of oculo-postural parameters of said individual when said individual performs a first task;—measuring (S6) at least one additional visual field (VFi) of said individual for one additional set of said oculo-postural parameters of said individual when said individual performs an additional task;—determining (S8) a functional visual space based on said first visual field (VF1) and said at least one additional visual field (VFi), said functional visual space being an envelope of said first visual field and said at least one additional visual field. The additional task differs from said first task and/or said additional set of oculo-postural parameters differs from said first set of oculo-postural parameters. A corresponding ophthalmic lens is also proposed.
    Type: Application
    Filed: December 21, 2017
    Publication date: March 25, 2021
    Inventors: José-Alain SAHEL, Angelo ARLEO, Anne-Catherine SCHERLEN, Delphine TRANVOUEZ-BERNARDIN
  • Patent number: 10955654
    Abstract: Disclosed is an imaging device including a light source arranged so as to generate an optical signal, an optical support coupled to the light source and arranged so as to project a luminous excitation signal with a substantially constant light intensity, from the light source to a body to be observed during the use of the device, and an asynchronous camera coupled to the optical support and designed so as to generate a signal including, for each pixel of a first pixel matrix, a signal sequence representing asynchronous events corresponding to variations of the light backscattered by the body to be observed for the pixel.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 23, 2021
    Assignees: SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SUD, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS—APHP
    Inventors: Guillaume Chenegros, Ryad Benosman, Nicolas Libert, Jacques Durenteau, Anatole Harrois, Serge Picaud, Jose-Alain Sahel
  • Publication number: 20210069346
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Application
    Filed: November 6, 2020
    Publication date: March 11, 2021
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Publication number: 20210002607
    Abstract: The disclosure pertains to a defined cell culture medium for the expansion of human retinal progenitors, comprising or consisting of a nutrient medium, a SHH-pathway activator and a GSK3 inhibitor. To the use of the defined cell culture medium for the expansion of retinal progenitors, as well as to an in vitro method for expanding retinal progenitors, comprising: (i) placing a culture of human retinal progenitors in a defined cell culture medium as defined in claims 1 to 8; and (ii) culturing the cells in said defined cell culture medium.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 7, 2021
    Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Sacha Reichman, Olivier Goureau, José-Alain Sahel
  • Patent number: 10857239
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 8, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Publication number: 20200318138
    Abstract: The present invention relates to improved constructs comprising the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 8, 2020
    Inventors: Thierry LEVEILLARD, Najate AÏT-ALI MAAMRI, Fréderic BLOND, José-Alain SAHEL, Géraldine PUEL, Emmanuelle CLERIN
  • Publication number: 20200277623
    Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3?UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3?UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.
    Type: Application
    Filed: September 18, 2019
    Publication date: September 3, 2020
    Inventors: Marisol CORRAL-DEBRINSKI, Jose-Alain SAHEL, Valerie KALTIMBACHER, Crystel BONNET
  • Publication number: 20200174023
    Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 4, 2020
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch